Market capitalization | $194.80m |
Enterprise Value | $-115.47m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.80 |
P/B ratio (TTM) P/B ratio | 0.54 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-187.37m |
Free Cash Flow (TTM) Free Cash Flow | $-144.19m |
Cash position | $339.70m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
7 Analysts have issued a CARGO Therapeutics forecast:
7 Analysts have issued a CARGO Therapeutics forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -7.05 -7.05 |
-
|
|
EBITDA | -180 -180 |
-
|
EBIT (Operating Income) EBIT | -187 -187 |
-
|
Net Profit | -168 -168 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.
Head office | United States |
CEO | Anup Radhakrishnan |
Employees | 167 |
Founded | 2019 |
Website | cargo-tx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.